FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3003269403> ?p ?o ?g. }

• W3003269403 endingPage "171" @default.
• W3003269403 startingPage "159" @default.
• W3003269403 abstract "Abstract OBJECTIVE To examine the effects of imidazoline and nonimidazoline α-adrenergic agents on aggregation of feline platelets. SAMPLE Blood samples from 12 healthy adult cats. PROCEDURES In 7 experiments, the effects of 23 imidazoline and nonimidazoline α-adrenoceptor agonists or antagonists on aggregation and antiaggregation of feline platelets were determined via a turbidimetric method. Collagen and ADP were used to initiate aggregation. RESULTS Platelet aggregation was not induced by α-adrenoceptor agonists alone. Adrenaline and noradrenaline induced a dose-dependent potentiation of ADP- or collagen-induced aggregation. Oxymetazoline and xylometazoline also induced a small potentiation of ADP-stimulated aggregation, but other α-adrenoceptor agonists did not induce potentiation. The α 2 -adrenoceptor antagonists and certain imidazoline α-adrenergic agents including phentolamine, yohimbine, atipamezole, clonidine, medetomidine, and dexmedetomidine inhibited adrenaline-potentiated aggregation induced by ADP or collagen in a dose-dependent manner. The imidazoline compound antazoline inhibited adrenaline-potentiated aggregation in a dose-dependent manner. Conversely, α 1 -adrenoceptor antagonists and nonimidazoline α-adrenergic agents including xylazine and prazosin were ineffective or less effective for inhibiting adrenaline-potentiated aggregation. Moxonidine also was ineffective for inhibiting adrenaline-potentiated aggregation induced by collagen. Medetomidine and xylazine did not reverse the inhibitory effect of atipamezole and yohimbine on adrenaline-potentiated aggregation. CONCLUSIONS AND CLINICAL RELEVANCE Adrenaline-potentiated aggregation of feline platelets may be mediated by α 2 -adrenoceptors, whereas imidazoline agents may inhibit in vitro platelet aggregation via imidazoline receptors. Imidazoline α-adrenergic agents may have clinical use for conditions in which there is platelet reactivity to adrenaline. Xylazine, medetomidine, and dexmedetomidine may be used clinically in cats with minimal concerns for adverse effects on platelet function." @default.
• W3003269403 created "2020-02-07" @default.
• W3003269403 creator A5086118131 @default.
• W3003269403 creator A5087146631 @default.
• W3003269403 date "2020-02-01" @default.
• W3003269403 modified "2023-10-16" @default.
• W3003269403 title "Effects of imidazoline and nonimidazoline α-adrenoceptor agonists and antagonists, including xylazine, medetomidine, dexmedetomidine, yohimbine, and atipamezole, on aggregation of feline platelets" @default.
• W3003269403 cites W1526329195 @default.
• W3003269403 cites W1529689640 @default.
• W3003269403 cites W1720110446 @default.
• W3003269403 cites W1966223081 @default.
• W3003269403 cites W1967325029 @default.
• W3003269403 cites W1970522214 @default.
• W3003269403 cites W1971151298 @default.
• W3003269403 cites W1971309654 @default.
• W3003269403 cites W1972301390 @default.
• W3003269403 cites W1973336543 @default.
• W3003269403 cites W1978887835 @default.
• W3003269403 cites W1982463900 @default.
• W3003269403 cites W1985502087 @default.
• W3003269403 cites W1988204563 @default.
• W3003269403 cites W1994291110 @default.
• W3003269403 cites W2001169118 @default.
• W3003269403 cites W2001902728 @default.
• W3003269403 cites W2004489556 @default.
• W3003269403 cites W2005678334 @default.
• W3003269403 cites W2006490359 @default.
• W3003269403 cites W2011826166 @default.
• W3003269403 cites W2012746514 @default.
• W3003269403 cites W2013947594 @default.
• W3003269403 cites W2014547742 @default.
• W3003269403 cites W2019130789 @default.
• W3003269403 cites W2027241860 @default.
• W3003269403 cites W2033078459 @default.
• W3003269403 cites W2043425461 @default.
• W3003269403 cites W2044909621 @default.
• W3003269403 cites W2054245604 @default.
• W3003269403 cites W2061264759 @default.
• W3003269403 cites W2064038235 @default.
• W3003269403 cites W2065022538 @default.
• W3003269403 cites W2065327374 @default.
• W3003269403 cites W2065505781 @default.
• W3003269403 cites W2068073349 @default.
• W3003269403 cites W2087637613 @default.
• W3003269403 cites W2094860317 @default.
• W3003269403 cites W2096176519 @default.
• W3003269403 cites W2110079268 @default.
• W3003269403 cites W2111980711 @default.
• W3003269403 cites W2116404715 @default.
• W3003269403 cites W2126871838 @default.
• W3003269403 cites W2134266856 @default.
• W3003269403 cites W2416038411 @default.
• W3003269403 cites W2417887381 @default.
• W3003269403 cites W2420229366 @default.
• W3003269403 cites W2546638295 @default.
• W3003269403 cites W2604300351 @default.
• W3003269403 cites W4233784269 @default.
• W3003269403 cites W4248970728 @default.
• W3003269403 doi "https://doi.org/10.2460/ajvr.81.2.159" @default.
• W3003269403 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31985287" @default.
• W3003269403 hasPublicationYear "2020" @default.
• W3003269403 type Work @default.
• W3003269403 sameAs 3003269403 @default.
• W3003269403 citedByCount "2" @default.
• W3003269403 countsByYear W30032694032021 @default.
• W3003269403 crossrefType "journal-article" @default.
• W3003269403 hasAuthorship W3003269403A5086118131 @default.
• W3003269403 hasAuthorship W3003269403A5087146631 @default.
• W3003269403 hasConcept C123605464 @default.
• W3003269403 hasConcept C134018914 @default.
• W3003269403 hasConcept C158453852 @default.
• W3003269403 hasConcept C170493617 @default.
• W3003269403 hasConcept C185592680 @default.
• W3003269403 hasConcept C2776312488 @default.
• W3003269403 hasConcept C2776814716 @default.
• W3003269403 hasConcept C2776885963 @default.
• W3003269403 hasConcept C2777676773 @default.
• W3003269403 hasConcept C2777953023 @default.
• W3003269403 hasConcept C2778399450 @default.
• W3003269403 hasConcept C2778938600 @default.
• W3003269403 hasConcept C2779520467 @default.
• W3003269403 hasConcept C2779591255 @default.
• W3003269403 hasConcept C2780013391 @default.
• W3003269403 hasConcept C2780042274 @default.
• W3003269403 hasConcept C2780141924 @default.
• W3003269403 hasConcept C2780795376 @default.
• W3003269403 hasConcept C2781302539 @default.
• W3003269403 hasConcept C42219234 @default.
• W3003269403 hasConcept C55493867 @default.
• W3003269403 hasConcept C71924100 @default.
• W3003269403 hasConcept C84393581 @default.
• W3003269403 hasConcept C98274493 @default.
• W3003269403 hasConceptScore W3003269403C123605464 @default.
• W3003269403 hasConceptScore W3003269403C134018914 @default.
• W3003269403 hasConceptScore W3003269403C158453852 @default.
• W3003269403 hasConceptScore W3003269403C170493617 @default.
• W3003269403 hasConceptScore W3003269403C185592680 @default.
• W3003269403 hasConceptScore W3003269403C2776312488 @default.

• next